Cargando…
Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes
BACKGROUND: Treatment guidelines recommend LDL-C as the primary target of therapy in patients with hypercholesterolemia. Moreover, combination therapies with lipid-lowering drugs that have different mechanisms of action are recommended when it is not possible to attain LDL-C targets with statin mono...
Autores principales: | Rotella, Carlo M, Zaninelli, Augusto, Le Grazie, Cristina, Hanson, Mary E, Gensini, Gian Franco |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918617/ https://www.ncbi.nlm.nih.gov/pubmed/20663203 http://dx.doi.org/10.1186/1476-511X-9-80 |
Ejemplares similares
-
Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)
por: Bardini, Gianluca, et al.
Publicado: (2010) -
Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review
por: Chauhan, Dhruva, et al.
Publicado: (2022) -
Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia
por: Visseren, F. L. J.
Publicado: (2011) -
Rhabdomyolysis after ezetimibe/simvastatin therapy in an HIV-infected patient
por: Chanson, Noemie, et al.
Publicado: (2008) -
Complementary Therapy to Target LDL Cholesterol: The Role of the Ezetimibe/Simvastatin Combination
por: Neal, Ryan C, et al.
Publicado: (2006)